Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (27048)	12/28/1998 9:23:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

The 12/28 LA Times Biz article mentioned Ontak latimes.com YEAR-END TECHNOLOGY SPECIAL Biotech Has a Strong Lineup Heading Into the New Year ... Ligand Pharmaceuticals relies on a different technology for Ontak, a drug for treating advanced cases of cutaneous T-cell lymphoma, an disfiguring form of cancer. The company is expecting a decision from the FDA in the next few weeks. The medication is a lab-created protein--a piece of diphtheria toxin fused to Interleukin-2, a natural chemical that seeks out diseased T-cells. In theory, the fused protein acts like a "smart" bomb--killing the lymphoma cells while sparing normal tissue.